Karuna Therapeutics IPO

6/28/2019

IPO

$83,200,000

We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments, to fund [i] the completion of our ongoing Phase 2 clinical trial and the completion of a planned Phase 3 clinical trial for the treatment of psychosis in schizophrenia; [ii] the completion of our planned Phase 1b clinical trial and the completion of a planned Phase 2 clinical trial for the treatment of psychosis in AD; [iii] the completion of our planned Phase 1b clinical trials for the cognitive and negative symptoms in schizophrenia; [iv] the completion of our planned Phase 1b clinical trial and the completion of a planned Phase 2 clinical trial for the treatment of pain; [v] the development and expansion of our pipeline, including other muscarinic candidates, formulations and derivatives; and [vi] for working capital and other general corporate activities.

Publicly-held

Biopharmaceutical

33 Arch St. 3110
Boston, MA 02110
USA

Karuna Therapeutics (Nasdaq: KRTX) is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.